ArticleCardiovascular drugs and therapy2026
Apixaban Versus LMWH in CAT/VTE: A Comment on Clinical and Methodological Heterogeneity.
Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We commend Huang et al. for separating treatment from postoperative prophylaxis in CAT/VTE. However, the pooled analysis still combines clinically distinct exposure patterns, heterogeneous LMWH comparators, and studies with different follow-up windows, which limits interpretability of the reported risk ratios. Observational before-after and quality-improvement studies are also vulnerable to secular trend bias, and acute treatment should not be merged with extended therapy. Future meta-analyses should use drug-specific stratification, time-standardized or hazard-based methods, concurrent controls, and phase-specific analyses to better estimate apixaban's effect while preserving clinically meaningful differences between indications and treatment phases in cancer-associated thrombosis across settings and improving decision-making in practice.
Indexed as
Identifiers
42734692What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.